EGFR and non-small cell lung carcinoma: Analyses of a panel of NSCLC lines demonstrated that the effect of αPD-L1 antibody on turnover of the ligand-stimulated EGFR protein amount was specific to cells harboring mutant EGFR (Fig. 4G).